Drug intelligence / Profile preview

HGS1029

Development stage: Phase 1
Lead developer: GSK
Modality: Small Molecules
Administration: Intravenous

Overview

HGS1029 is a small molecule inhibitor of apoptosis proteins (IAPs), designed to block the biological activity of IAP proteins, thereby allowing apoptosis to proceed and causing cancer cells to die. It was initially developed by Aegera Therapeutics and later acquired by Human Genome Sciences for further development. HGS1029 has shown significant anti-tumor activity alone and in combination with other anti-cancer agents in preclinical studies.

Other names: AEG40826AEG-40826AEG 40826

Targets

IAP (Inhibitor of apoptosis protein family)

Beyond the preview

Go deeper on HGS1029.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HGS1029.

Explore the full profile